Several published preclinical studies have demonstrated that anti-CD47 antibody treatment synergizes with tumor targeting IgG1 antibodies (among which anti-CD20, anti-PD-L1, anti-CD38 or anti-EGFR mAbs) by combining Fcγ receptor (FcγR)-dependent and FcγR-independent stimulation of phagocytosis as well as other FcR-dependent mechanisms such as antibody-dependent cell cytotoxicity (ADCC) (15, 18, 20, 26–28) leading to several ongoing clinical trials. The gene discussed is FCGR2A; the disease is neoplasm.